Trump presses FDA to fast-track potential coronavirus drugs
By Reuters Staff WASHINGTON (Reuters) - U.S. President Donald Trump on Thursday called on U.S. health regulators to expedite potential therapies aimed at treating COVID-19 amid the fast-spreading coronavirus outbreak, saying it could lead to a breakthrough while a vaccine is still under development.
coronavirus drugs" src="https://images.firstpost.com/wp-content/uploads/reuters/03-2020/20/2020-03-19T164223Z_1_LYNXMPEG2I1PF_RTROPTP_2_HEALTH-CORONAVIRUS-USA-TRUMP.jpg" alt="Trump presses FDA to fasttrack potential coronavirus drugs" width="300" height="225" />
By Reuters Staff
WASHINGTON (Reuters) - U.S. President Donald Trump on Thursday called on U.S. health regulators to expedite potential therapies aimed at treating COVID-19 amid the fast-spreading coronavirus outbreak, saying it could lead to a breakthrough while a vaccine is still under development.
Trump, speaking at a news conference, pointed to efforts on Gilead Sciences Inc's experimental antiviral drug Remdesivir and the generic antimalarial drug hydroxychloroquine, saying he had called on the U.S. Food and Drug Administration to streamline its regulatory approval process.
"We have to remove every barrier," Trump said.
Trials on potential coronavirus therapies are already in the works, and it was unclear how Trump's call for faster experimental testing process could further expedite an effective treatment.
"It could be a game changer or maybe not," Trump told reporters.
FDA Commissioner Stephen Hahn said his agency was working quickly to examine all possibilities.
"In the short term, we're looking at drugs that are already approved for other indications," Hahn said.
This story has not been edited by Firstpost staff and is generated by auto-feed.
Pulitzer Prize-winning photojournalist Danish Siddiqui killed in Afghanistan: Politicans, journalists pay tributes
The Pulitzer prize winner, who was in Kandahar covering operations against Taliban, was killed when he was riding along with the Afghan Special Forces
Siddiqui had also covered the 2020 Delhi riots, COVID-19 pandemic, Nepal earthquake in 2015 and the protests in Hong Kong
Danish's photographs were not just documentation, but the work of someone who went down to eye-level, as they say in photographic parlance.